Clinical trials: Neoadjuvant Treatment
Melanoma Stage III, Melanoma Stage IV
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
The purpose of this study is to assess rate of disease relapse and hazard rate of disease relapse after neoadjuvant therapy based on the statuses of pathologic complete response or non-pathologic complete response, and…
- Conditions
- Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation
- Trial name
- NCT04741997
- Testing
- Encorafenib Pill, Binimetinib Pill, Nivolumab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Pancreatic Cancer, Colo-rectal Cancer
Prehabilitation in High-risk Oncologic Surgery
The goal of this clinical study is to learn whether a prehabilitation program can improve recovery after major abdominal surgery in adults with cancer who are receiving treatment before surgery.
- Conditions
- Pancreatic Cancer, Colo-rectal Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT07638410
- Testing
- Multidisciplinary Prehabilitation Program
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Fox Chase Cancer Center
Non-small Cell Lung Cancer
Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer
This is a prospective, single-arm, multi-center, phase II clinical study to evaluate the efficacy and safety of Envafolimab injection (PD-L1) combined with Disitamab Vedotin (HER2 ADC) and Carboplatin for resectable, HER2-Mutant…
- Trial name
- neovision (NCT06734182)
- Testing
- Envafolimab injections+intravenous Disitamab Vedotin+carboplatin
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Guangdong Provincial People's Hospital
Cholangiocarcinoma, Intrahepatic
Liver Transplant for Stable, Advanced Intrahepatic Cholangiocarcinoma
Diagnosis of intrahepatic cholangiocarcinoma (iCCA) is an increasingly common form of primary liver cancer, but patients with this diagnosis are not currently eligible for LT.
- Trial name
- NCT04195503
- Testing
- Liver Transplantation
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University Health Network, Toronto
Breast Cancer
Feasibility Study of Biomarkers of Response to Neoadjuvant Paclitaxel in Locally Advanced Breast Cancer
The purpose of this study is to determine if the investigators are able to locate and measure certain characteristics in breast cancer tumors that have been treated with paclitaxel that may correlate to how well the cancer will…
- Trial name
- NCT01263613
- Testing
- tumor biopsy and blood draw
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Wisconsin, Madison
Esophageal Squamous Cell Carcinoma
Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy
Comparison of esophagectomy with Two-field Versus Three-field lymphadenectomy in locally advanced ESCC patients after neoadjuvant therapy
- Trial name
- NCT05420480
- Testing
- Two-Field lymph node dissection, Three-Field lymph node dissection
- Where
- China
- Volunteers
- 323 people
- Sponsor
- Shanghai Zhongshan Hospital
Intrahepatic Cholangiocarcinoma, PD1 Antibody
Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
A randomized controlled, multicenter, open, seamless phase II-III clinical trial is designed to target patients with resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors which has extremely low…
- Conditions
- Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib, Gemox Chemotherapy
- Trial name
- NCT04669496
- Testing
- Neoadjuvant treatment
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Shanghai Zhongshan Hospital
Breast Cancer
Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer
The purpose of this study is to compare neo-adjuvant therapy of cytotoxic chemotherapy versus GnRHa with tamoxifen , of response rate(RR) in patients of hormone responsive and HER2 negative, lymph node positive, primary breast…
- Trial name
- NEST (NCT01622361)
- Testing
- Adriamycin+Cyclophosphamide>Docetaxel, GnRHa with Tamoxifen
- Where
- South Korea
- Volunteers
- 290 people
- Sponsor
- Asan Medical Center
Ovarian Cancer
Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
This is a prospective, interventional, single-arm, open-label, phase II study to evaluate the safety and efficacy of niraparib monotherapy as neoadjuvant therapy in patients with advanced ovarian cancer, primary peritoneal…
- Trial name
- NCT04507841
- Testing
- Niraparib
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Tongji Hospital
Breast Cancer
Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer
Neoadjuvant chemotherapy (NAC) is increasingly used for early-stage operable breast cancer. Response of breast cancer to NAC is correlated with survival: patients who obtain greatest survival advantage are those who attain…
- Trial name
- BERNAQ (NCT02365805)
- Testing
- Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel, Epirubicin + Cisplatin + Fluorouracil, Docetaxel + Ciclofosfamide
- Where
- 7 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Locally Advanced Rectal Carcinoma, Circulating Tumor DNA
Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer
Rectal cancer still remains one of the most popular tumors, however, distance metastasis still remains as high as 30% and the long-term survival outcomes are still unsatisfying.
- Trial name
- CINTS-R (NCT05601505)
- Testing
- circulating tumor DNA
- Where
- China
- Volunteers
- 470 people
- Sponsor
- Peking Union Medical College Hospital
Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
Esophageal cancer, which has a low 5-year overall survival rate (<20%) is increasing in incidence. Previous studies have shown that Hedgehog, AKT, and angiogenic signaling pathways are activated in a significant number of…
- Conditions
- Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastroesophageal Junction Carcinoma
- Trial name
- NCT05563766
- Testing
- Itraconazole
- Where
- 7 sites in United States
- Volunteers
- 78 people
- Sponsor
- VA Office of Research and Development
HER2-negative Early Breast Cancer
Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients
Neoadjuvant treatment is an important treatment for early breast cancer patients. Patients with triple negative subtype who achieved pCR after neoadjuvant treatment would have longer survival.
- Trial name
- NCT04836156
- Testing
- neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer, neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Peking University People's Hospital
Soft Tissue Sarcoma
Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma
This research is being done with the aim of developing a more effective treatment than standard radiotherapy and surgery alone. Although standard treatment is frequently successful, some patients do not respond well to this…
- Trial name
- SUNXRT (NCT00753727)
- Testing
- Sunitinib malate, Radiotherapy
- Where
- Australia
- Volunteers
- 26 people
- Sponsor
- Australasian Sarcoma Study Group
Cervical Cancer
A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer
This is a phase II, prospective, single-arm, multicenter, open-label study to evaluate the efficacy and safety of sacituzumab tirumotecan in combination with iparomlimab and tuvonralimab as neoadjuvant therapy in patients with…
- Trial name
- NCT07348861
- Testing
- Sacituzumab tirumotecan plus Iparomlimab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Zheng Min
Gastric Cancer
"Phase III Randomized Trial Comparing D2 vs D3 Lymphadenectomy With Gastric Cancer Following Neoadjuvant Chemotherapy
Stomach cancer is the second most common cause of cancer-related deaths in India. Curative surgery offers the only chance of improving survival in this cancer.
- Trial name
- NCT02139605
- Testing
- D3 Lymphadenectomy
- Where
- India
- Volunteers
- 400 people
- Sponsor
- Tata Memorial Centre
Breast Cancer Invasive
Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy
The primary aim is to evaluate the efficacy of neoadjuvant SBRT combined with PD-1 monoclonal antibody and chemotherapy in patients with triple-negative breast cancer, with the endpoint being the pCR rate-defined as the…
- Trial name
- NCT06691594
- Testing
- neoadjuvant SBRT combined with PD-1 monoclonal antibody and chemotherapy
- Volunteers
- 20 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Surgery, Neoadjuvant Chemotherapy
Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancreatic Cancer
This trial aimed to determine whether neoadjuvant chemoradiotherapy improves overall survival compared with upfront surgery, both followed by adjuvant chemotherapy in patients with resectable and borderline resectable pancreatic…
- Conditions
- Surgery, Neoadjuvant Chemotherapy, Management, Resectable Pancreatic Cancer
- Trial name
- NCT06978322
- Testing
- Immediate surgery, Neoadjuvant chemotherapy
- Where
- Egypt
- Volunteers
- 81 people
- Sponsor
- Minia University
Gastric / Gastroesophageal Junction Adenocarcinoma
Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology
This study is to evaluate the efficacy and safety of different postoperative adjuvant regimens in patients with resectable adenocarcinoma of the esophagogastric junction who underwent radical surgery after neoadjuvant…
- Trial name
- NCT07161453
- Testing
- SOX plus PD-1 inhibitor, PD-1 / PD-L1 monoclonal antibody, SOX Chemotherapy
- Volunteers
- 500 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma
Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma
This study is a superiority multi-center, open-label, phase III randomized controlled trial. It will further verify the clinical value of xidili single-antibody combined with chemotherapy (albumin paclitaxel and carboplatin) in…
- Conditions
- Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma, Early-stage Oral Cancer
- Trial name
- NCT07827872
- Testing
- Sintilimab, Nab-Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 300 people
- Sponsor
- caohaotian
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.